Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$107.53 USD
+0.67 (0.63%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $107.69 +0.16 (0.15%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum C VGM
Balance Sheet
Fiscal Year End for Abbott Laboratories falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 7,279 | 10,170 | 10,249 | 7,148 | 4,140 |
Receivables | 6,565 | 6,218 | 6,487 | 6,414 | 5,425 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 6,570 | 6,173 | 5,157 | 5,012 | 4,316 |
Other Current Assets | 2,256 | 2,663 | 2,346 | 1,867 | 1,786 |
Total Current Assets | 22,670 | 25,224 | 24,239 | 20,441 | 15,667 |
Net Property & Equipment | 10,154 | 9,162 | 8,959 | 9,029 | 8,038 |
Investments & Advances | 799 | 766 | 816 | 821 | 883 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 7,097 | 6,033 | 5,212 | 3,729 | 3,079 |
Intangibles | 32,494 | 33,253 | 35,970 | 38,528 | 40,220 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 73,214 | 74,438 | 75,196 | 72,548 | 67,887 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 213 | 201 |
Accounts Payable | 4,295 | 4,607 | 4,408 | 3,946 | 3,252 |
Current Portion Long-Term Debt | 1,080 | 2,251 | 754 | 7 | 1,277 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 7,019 | 7,401 | 6,806 | 6,581 | 5,272 |
Income Taxes Payable | 492 | 343 | 306 | 362 | 226 |
Other Current Liabilities | 955 | 887 | 831 | 798 | 635 |
Total Current Liabilities | 13,841 | 15,489 | 13,105 | 11,907 | 10,863 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 13,599 | 14,522 | 17,296 | 18,527 | 16,661 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 6,947 | 7,522 | 8,771 | 9,111 | 9,062 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 34,387 | 37,533 | 39,172 | 39,545 | 36,586 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 24,869 | 24,709 | 24,470 | 24,145 | 23,853 |
Capital Surplus | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | 37,554 | 35,257 | 31,528 | 27,627 | 25,847 |
Other Equity | -7,615 | -7,832 | -8,152 | -8,727 | -8,252 |
Treasury Stock | 15,981 | 15,229 | 11,822 | 10,042 | 10,147 |
Total Shareholder's Equity | 38,827 | 36,905 | 36,024 | 33,003 | 31,301 |
Total Liabilities & Shareholder's Equity | 73,214 | 74,438 | 75,196 | 72,548 | 67,887 |
Total Common Equity | 38,827 | 36,905 | 36,024 | 33,003 | 31,301 |
Shares Outstanding | 1,736.00 | 1,743.50 | 1,768.20 | 1,772.30 | 1,768.40 |
Book Value Per Share | 22.37 | 21.17 | 20.37 | 18.62 | 17.70 |
Fiscal Year End for Abbott Laboratories falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 7,279 | 7,047 | 8,155 | 9,532 |
Receivables | NA | 6,565 | 6,499 | 6,172 | 6,020 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 6,570 | 6,650 | 6,871 | 6,673 |
Other Current Assets | NA | 2,256 | 2,468 | 2,307 | 2,152 |
Total Current Assets | NA | 22,670 | 22,664 | 23,505 | 24,377 |
Net Property & Equipment | NA | 10,154 | 9,552 | 9,449 | 9,282 |
Investments & Advances | NA | 799 | 788 | 799 | 776 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 7,097 | 6,527 | 6,509 | 6,426 |
Intangibles | NA | 32,494 | 32,559 | 33,092 | 32,933 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 73,214 | 72,090 | 73,354 | 73,794 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 4,295 | 3,961 | 4,211 | 4,167 |
Current Portion Long-Term Debt | NA | 1,080 | 1,051 | 2,284 | 2,285 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 7,019 | 6,826 | 6,696 | 6,856 |
Income Taxes Payable | NA | 492 | 318 | 273 | 334 |
Other Current Liabilities | NA | 955 | 886 | 886 | 888 |
Total Current Liabilities | NA | 13,841 | 13,042 | 14,350 | 14,530 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 13,599 | 14,477 | 14,562 | 14,615 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 6,877 | 7,038 | 7,417 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 34,387 | 34,396 | 35,950 | 36,562 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 24,869 | 24,727 | 24,612 | 24,488 |
Capital Surplus | NA | 0 | 0 | 0 | 0 |
Retained Earnings | NA | 37,554 | 36,920 | 36,355 | 35,868 |
Other Equity | NA | -7,615 | -8,267 | -7,841 | -7,817 |
Treasury Stock | NA | 15,981 | 15,686 | 15,722 | 15,307 |
Total Shareholder's Equity | NA | 38,827 | 37,694 | 37,404 | 37,232 |
Total Liabilities & Shareholder's Equity | NA | 73,214 | 72,090 | 73,354 | 73,794 |
Total Common Equity | 0 | 38,827 | 37,694 | 37,404 | 37,232 |
Shares Outstanding | 1,735.10 | 1,736.00 | 1,736.00 | 1,735.30 | 1,738.90 |
Book Value Per Share | 0.00 | 22.37 | 21.71 | 21.55 | 21.41 |